Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Glioblastoma 41Glioma 10Brain Neoplasms 9Gliosarcoma 8Astrocytoma 7Neuroblastoma 6Small Cell Lung Carcinoma 4Oligodendroglioma 4Neoplasms 4Medulloblastoma 4Sarcoma, Ewing 3Sarcoma 3Melanoma 3Somatostatinoma 2Rhabdomyosarcoma 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Neuroendocrine Tumors 2Lung Neoplasms 2Ependymoma 2Diffuse Intrinsic Pontine Glioma 2Desmoplastic Small Round Cell Tumor 2Central Nervous System Neoplasms 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Supratentorial Neoplasms 1Spinal Cord Neoplasms 1Rhabdoid Tumor 1Prostatic Neoplasms 1

Interventions

Temozolomide 2Capecitabine 2lutetium Lu 177 dotatate 1cabozantinib 1atezolizumab 1abemaciclib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Adenoma, Islet Cell × Temozolomide × Clear all
NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
31 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡